Epigenetics in Psychiatry covers all major areas of psychiatry in which extensive epigenetic research has been performed, fully encompassing a diverse and maturing field, including drug addiction, bipolar disorder, epidemiology, cognitive disorders, and the uses of putative epigenetic-based psychotropic drugs. Uniquely, each chapter correlates epigenetics with relevant advances across genomics, transcriptomics, and proteomics. The book acts as a catalyst for further research in this potentially very important and useful area of psychiatry.
The elucidation of basic principles of epigenetic biology points to the creation of more optimal and effective therapies for major classes of psychiatric disease. In this regard, epigenetic therapy, the use of drugs to correct epigenetic defects, may help in the pharmacotherapy of patients with these disorders. With time, such advances may eventually point to replacements for psychotropic drugs presently of symptomatic value and low efficacy. Moreover, there is evidence to suggest that other forms of treatment commonly used in the management of psychiatric disorders, like psychotherapy and electroconvulsive therapy, may also act by epigenetic mechanisms.
Die Inhaltsangabe kann sich auf eine andere Ausgabe dieses Titels beziehen.
Jacob Peedicayil has published 46 review papers, 3 book chapters and is engaged in various editorial review boards and journal positions. His interests include theoretical research in psychiatric epigenetics and muscle-based pharmacology.
Dr. Grayson has been interested in mechanisms associated with gene expression for over 20 years. He joined the laboratory of Dr. James E. Darnell, Jr. at the Rockefeller University on 1984 to study cell-type specific transcription factors. This led to the identification of HNF3A as a hepatocyte nuclear factor important for activating the expression of multiple genes in hepatocytes. In 1988, Dr. Grayson joined the Fidia-Georgetown Institute for the Neurosciences and with the support of Dr. Erminio Costa, initiated a program in studying gene expression in neurons. From 1994-1998, he moved to the Allegheny University of the Health Sciences in Pittsburgh and developed a program in molecular psychiatry. He continued his interests in psychiatry and joined the Psychiatric Institute in 1998. This represented a unique opportunity to join his long time collaborators, Drs. Costa and Guidotti to pursue molecular underpinnings of schizophrenia. Dr. Grayson has received NRSA post-doctoral support, R01 and K04 funding from the NIH over the years. He has published over 100 papers in peer-reviewed journals and actively reviews NIH grants and post-doctoral fellowships. In addition, Dr. Grayson has been invited to speak at numerous national and international meetings.
"This exciting new area of research is covered by this topnotch, comprehensive new book. I highly recommend it to anyone interested in keeping up to date with modern psychiatry...Score: 86 - 3 Stars"--Doodys.com, January 23, 2015
„Über diesen Titel“ kann sich auf eine andere Ausgabe dieses Titels beziehen.